Prosecution Insights
Prosecution Insights
57 pending office actions • 26 art units • 50 examiners • 0 of 57 (0%) have an AI response strategy ready • 69 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 33 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 33 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 6 (11%) |
| §103 only | 13 (23%) |
| §102 only | 3 (5%) |
| §112 only | 7 (12%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 5 (9%) |
| Multi-statute (no §101) | 18 (32%) |
| No statute on record | 3 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 2 | 71.0% | +0.3% |
| VIVLEMORE, TRACY ANN | 2 | 73.0% | +6.7% |
| BENAVIDES, JENNIFER ANN | 2 | 51.3% | +48.6% |
| MARTINEZ, TARA L | 2 | 62.7% | +65.0% |
| BRAUN, MADELINE E | 2 | 67.6% | +26.4% |
| KENNEDY, SARAH JANE | 2 | 0.0% | +0.0% |
| LADD, CAROLYN LOUISE | 2 | 57.0% | +47.9% |
| MYERS, CARLA J | 1 | 49.0% | +46.6% |
| ABBAS, SYED JARAR | 1 | 0.0% | +0.0% |
| VASSELL, MEREDITH ABBOTT | 1 | 29.7% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | HEITMEIER, KENDALL NICOLE | 182d overdue |
| 17402018 | GENETIC ABNORMALITIES IN PLASMA CELL DYSCRASIAS | GOLDBERG, JEANINE ANNE | 131d overdue |
| 17473362 | METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES USING FNDC5 | MARTINEZ, TARA L | 99d overdue |
| 18016209 | METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF CORONAVIRUS INFECTION | REDDIG, PETER J | 73d overdue |
| 17877195 | COMBINATION THERAPY WITH NEOANTIGEN VACCINE | GODDARD, LAURA B | 19d overdue |
| 18026746 | METHODS OF TREATING AN INDIVIDUAL THAT HAS FAILED AN ANTI-PD-1/ANTI-PD-L1 THERAPY | BENAVIDES, JENNIFER ANN | 18d overdue |
| 18031257 | GERMLINE BIOMARKERS OF CLINICAL RESPONSE AND BENEFIT TO IMMUNE CHECKPOINT INHIBITOR THERAPY | HINES, JANA A | 15d overdue |
| 17761040 | COMPOSITIONS AND METHODS FOR TREATMENT OF A POOR PROGNOSIS SUBTYPE OF COLORECTAL CANCER | KENNEDY, SARAH JANE | 11d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17473362 | METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES USING FNDC5 | MARTINEZ, TARA L | 99d overdue |
| 17934553 | 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | BRAUN, MADELINE E | 79d overdue |
| 17284250 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LADD, CAROLYN LOUISE | 25d overdue |
| 18026746 | METHODS OF TREATING AN INDIVIDUAL THAT HAS FAILED AN ANTI-PD-1/ANTI-PD-L1 THERAPY | BENAVIDES, JENNIFER ANN | 18d overdue |
| 19098448 | IDENTIFICATION OF SOMATIC OR GERMLINE ORIGIN FOR CELL-FREE DNA | VASSELL, MEREDITH ABBOTT | 16d |
| 17919008 | ANTIVIRAL STRUCTURALLY-STABILIZED ACE2 HELIX 1 PEPTIDES AND USES THEREOF | MARTINEZ, TARA L | 22d |
| 19397515 | UNIVERSAL EARLY CANCER DIAGNOSTICS | MYERS, CARLA J | — |
| 17621057 | HCK DEGRADERS AND USES THEREOF | LADD, CAROLYN LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 7 |
| 1624 | 5 |
| 1621 | 3 |
| 1675 | 3 |
| 1638 | 3 |
| 1658 | 3 |
| 1643 | 3 |
| 1683 | 3 |
| 1623 | 2 |
| 1654 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19397515 | UNIVERSAL EARLY CANCER DIAGNOSTICS | MYERS, CARLA J | 1682 | §101§102§103§112DP | Final Rejection | — | Pending | Nov 21, 2025 |
| 19371802 | Methods of Treating Red Blood Cell Disorders | ABBAS, SYED JARAR | 1674 | §103§112 | Non-Final OA | — | Pending | Oct 28, 2025 |
| 19098448 | IDENTIFICATION OF SOMATIC OR GERMLINE ORIGIN FOR CELL-FREE DNA | VASSELL, MEREDITH ABBOTT | 1687 | §101DP | Final Rejection | 16d | Pending | Apr 02, 2025 |
| 18960980 | SYSTEMS, COMPOSITIONS AND METHODS FOR IDENTIFYING E3 LIGASE SUBSTRATES BY UBIQUITIN BIOTINYLATION | PAK, YONG D | — | §112 | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18720202 | BCL6 DEGRADERS AND USES THEREOF | RZECZYCKI, PHILLIP MATTHEW | — | §102§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18710722 | ENZYME-FREE ISOTHERMAL EXPONENTIAL AMPLIFICATION | WILDER, CYNTHIA B | — | §103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18399092 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | YOO, SUN JAE | 1621 | §112 | Non-Final OA | 26d overdue | Pending | Dec 28, 2023 |
| 18541680 | METHODS AND COMPOSITIONS FOR PREDICTING AND PREVENTING RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA | DAVIS, BRIAN J | 1614 | §102§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18567873 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | BELL, SARA ELIZABETH | 1625 | §102 | Final Rejection | — | Pending | Dec 07, 2023 |
| 18289568 | ANTIBODIES AGAINST ALK AND METHODS OF USE THEREOF | WEIDNER, ADAM M | 1675 | §112 | Final Rejection | — | Pending | Nov 05, 2023 |
| 18283264 | ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS | BURKETT, DANIEL JOHN | 1624 | §102§112 | Final Rejection | — | Pending | Sep 21, 2023 |
| 18241186 | SUBSTITUTED 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONES FOR THE TREATMENT OF SARCOMA | JARRELL, NOBLE E | 1699 | §103Other | Non-Final OA | 32d overdue | Pending | Aug 31, 2023 |
| 18448941 | SELECTIVE DEGRADATION OF WILD-TYPE DNA AND ENRICHMENT OF MUTANT ALLELES USING NUCLEASE | SISSON, BRADLEY L | 1682 | §103§112 | Non-Final OA | — | Pending | Aug 13, 2023 |
| 18272184 | METHODS AND COMPOSITIONS FOR IDENTIFYING NEUROENDOCRINE PROSTATE CANCER | DAUNER, JOSEPH G | 1682 | §101§102§103§112 | Non-Final OA | 63d | Pending | Jul 13, 2023 |
| 18315472 | N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | WILLIS, DOUGLAS M | 1624 | §103 | Final Rejection | 70d | Pending | May 10, 2023 |
| 18141278 | COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS | VIVLEMORE, TRACY ANN | 1638 | §102§112DP | Final Rejection | — | Pending | Apr 28, 2023 |
| 18031257 | GERMLINE BIOMARKERS OF CLINICAL RESPONSE AND BENEFIT TO IMMUNE CHECKPOINT INHIBITOR THERAPY | HINES, JANA A | 1645 | §101 | Final Rejection | 15d overdue | Pending | Apr 11, 2023 |
| 18026746 | METHODS OF TREATING AN INDIVIDUAL THAT HAS FAILED AN ANTI-PD-1/ANTI-PD-L1 THERAPY | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112Other | Final Rejection | 18d overdue | Pending | Mar 16, 2023 |
| 18113539 | STABILIZED PEPTIDE-MEDIATED TARGETED PROTEIN DEGRADATION | FISCHER, JOSEPH | 1658 | §102§103§112Other | Final Rejection | — | Pending | Feb 23, 2023 |
| 18020493 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | NOLAN, JASON MICHAEL | 1623 | §103 | Final Rejection | — | Pending | Feb 09, 2023 |
| 18019851 | THERAPEUTIC TARGETING OF PHOSPHATE DYSREGULATION IN CANCER VIA THE XPR1:KIDINS220 PROTEIN COMPLEX | REYNOLDS, FRED H | 1658 | §103§112 | Final Rejection | — | Pending | Feb 06, 2023 |
| 18018207 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | MARTIN, KEVIN STEPHEN | 1624 | §112 | Final Rejection | 31d overdue | Pending | Jan 26, 2023 |
| 18016209 | METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF CORONAVIRUS INFECTION | REDDIG, PETER J | 1646 | §102§103§112 | Non-Final OA | 73d overdue | Pending | Jan 13, 2023 |
| 18061369 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA | SHELTON, SYNPHANE LA'SHAWN | 1652 | §112 | Final Rejection | 26d | Pending | Dec 02, 2022 |
| 17927529 | BISPECIFIC MOLECULES FOR SELECTIVELY MODULATING T CELLS | CHATTIN, AMY MARIE | 1643 | §103§112 | Non-Final OA | 15d | Pending | Nov 23, 2022 |
| 17919008 | ANTIVIRAL STRUCTURALLY-STABILIZED ACE2 HELIX 1 PEPTIDES AND USES THEREOF | MARTINEZ, TARA L | 1654 | §101§102§103§112Other | Non-Final OA | 22d | Pending | Oct 14, 2022 |
| 17934553 | 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | BRAUN, MADELINE E | 1624 | §112 | Non-Final OA | 79d overdue | Pending | Sep 22, 2022 |
| 17910776 | METHODS FOR GENERATING ENGINEERED MEMORY-LIKE NK CELLS AND COMPOSITIONS THEREOF | WILSON, MICHAEL C | 1638 | §103 | Final Rejection | — | Pending | Sep 09, 2022 |
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | HEITMEIER, KENDALL NICOLE | 1621 | §102§103§112 | Final Rejection | 182d overdue | Pending | Aug 23, 2022 |
| 17877195 | COMBINATION THERAPY WITH NEOANTIGEN VACCINE | GODDARD, LAURA B | 1642 | §103§112 | Final Rejection | 19d overdue | Pending | Jul 29, 2022 |
| 17785561 | STRUCTURALLY-STABILIZED ONCOLYTIC PEPTIDES AND USES THEREOF | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103Other | Non-Final OA | 66d overdue | Pending | Jun 15, 2022 |
| 17832911 | Immunomodulation by IAP Inhibitors | HOWELL, THEODORE R | 1628 | Other | Non-Final OA | 22d | Pending | Jun 06, 2022 |
| 17774002 | SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADERS AND METHODS OF USE THEREOF | GAUGER, PAUL RANDALL | 1629 | §103 | Final Rejection | 31d overdue | Pending | May 03, 2022 |
| 17725407 | METHODS AND COMPOSITIONS FOR THE POSITIVE SELECTION OF PROTEIN DESTABILIZERS | LEE, JAE W | 1656 | §103 | Non-Final OA | 8d | Pending | Apr 20, 2022 |
| 17767035 | COMPOSITIONS AND METHODS FOR TREATING CYTOTOXIC T CELL RESISTANT TUMORS | LU, CHENG | 1642 | §103§112Other | Non-Final OA | 16d | Pending | Apr 06, 2022 |
| 17766189 | IMMUNOMODULATORY IMIDE DRUGS AS ZETA-CHAIN-ASSOCIATED PROTEIN KINASE 70 (ZAP70) AGONISTS AND USES THEREOF | WHITE, DAWANNA SHAR-DAY | 1627 | §102Other | Non-Final OA | 5d | Pending | Apr 01, 2022 |
| 17761040 | COMPOSITIONS AND METHODS FOR TREATMENT OF A POOR PROGNOSIS SUBTYPE OF COLORECTAL CANCER | KENNEDY, SARAH JANE | 1682 | §103 | Final Rejection | 11d overdue | Pending | Mar 16, 2022 |
| 17687246 | COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS | VIVLEMORE, TRACY ANN | 1638 | §112DPOther | Final Rejection | 70d | Pending | Mar 04, 2022 |
| 17640016 | CRISPR EFFECTOR SYSTEM BASED MULTIPLEX CANCER DIAGNOSTICS | HOPPE, EMMA RUTH | 1683 | §103§112DP | Non-Final OA | — | Pending | Mar 03, 2022 |
| 17639532 | RAPID PREDICTION OF DRUG RESPONSIVENESS | KENNEDY, SARAH JANE | 1682 | §101§103 | Final Rejection | 8d overdue | Pending | Mar 01, 2022 |
| 17634465 | IMMUNE SIGNATURES PREDICTIVE OF RESPONSE TO PD-1 BLOCKADE IN RICHTER'S TRANSFORMATION | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103§112 | Non-Final OA | — | Pending | Feb 10, 2022 |
| 17628794 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CORNET, JEAN P | 1628 | §103 | Final Rejection | 28d | Pending | Jan 20, 2022 |
| 17621057 | HCK DEGRADERS AND USES THEREOF | LADD, CAROLYN LOUISE | 1622 | DP | Final Rejection | — | Pending | Dec 20, 2021 |
| 17595671 | COMBINATION THERAPY | SKOKO III, JOHN JOSEPH | 1643 | §103DP | Final Rejection | 72d overdue | Pending | Nov 22, 2021 |
| 17605956 | 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS | BRAUN, MADELINE E | 1624 | §112DP | Final Rejection | — | Pending | Oct 22, 2021 |
| 17605207 | COMPOSITIONS AND METHODS CHARACTERIZING METASTASIS | LEVIN, JOEL D | 1633 | Other | Final Rejection | 26d overdue | Pending | Oct 20, 2021 |
| 17473362 | METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES USING FNDC5 | MARTINEZ, TARA L | 1654 | §101§112 | Non-Final OA | 99d overdue | Pending | Sep 13, 2021 |
| 17402018 | GENETIC ABNORMALITIES IN PLASMA CELL DYSCRASIAS | GOLDBERG, JEANINE ANNE | 1682 | §103§112 | Non-Final OA | 131d overdue | Pending | Aug 13, 2021 |
| 17419965 | SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS | YOO, SUN JAE | 1621 | — | Final Rejection | 15d overdue | Pending | Jun 30, 2021 |
| 17284250 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LADD, CAROLYN LOUISE | 1622 | §103Other | Non-Final OA | 25d overdue | Pending | Apr 09, 2021 |
| 17213417 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION | MOSS, NATALIE M | 1653 | §103§112 | Final Rejection | — | Pending | Mar 26, 2021 |
| 17268941 | DNA AMPLIFICATION METHOD FOR PROBE GENERATION | POHNERT, STEVEN C | 1683 | §103§112 | Final Rejection | — | Pending | Feb 16, 2021 |
| 17265139 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | PECKHAM, RICHARD GRANT | 1627 | §102 | Non-Final OA | 42d overdue | Pending | Feb 01, 2021 |
| 16982333 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BENAVIDES, JENNIFER ANN | 1675 | §103 | Final Rejection | — | Pending | Sep 18, 2020 |
| 16825269 | BORONIC ESTER PRODRUGS AND USES THEREOF | BAKSHI, PANCHAM | 1623 | §112 | Non-Final OA | — | Pending | Mar 20, 2020 |
| 16739866 | FUNCTIONAL ANALYSIS OF CANCER CELLS | LU, FRANK WEI MIN | 1683 | §103 | Non-Final OA | 105d overdue | Pending | Jan 10, 2020 |
| 15768853 | POLYMERASE Q AS A TARGET IN HR-DEFICIENT CANCERS | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | — | Pending | Apr 17, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial